PARI scoring system
| RF/comorbid condition . | 2-y TRM (95% CI) . | Multivariate analysis (HR) . | Weight . |
|---|---|---|---|
| Donor type | |||
| Mismatched donor | 24.1% (18.2- 30.5) | 2.14 | 2 |
| Conditioning regimen | |||
| TBI | 18.4% (10.9-27.5) | 1.75 | 2 |
| Infection | |||
| Presence of respiratory viral infection D-10-D0 | 31% (15-49) | 2.09 | 2 |
| Lung disease | |||
| Any respiratory structural abnormality | 23% (6-47) | 2.15 | 2 |
| CNS disease | |||
| Any CNS abnormality (CNS infection, PRES, epilepsy, and CNS structural abnormality) | 47% (29-63) | 3.68 | 3 |
| Gut disease | |||
| Active infectious diarrhea | 42% (15-67) | 1.61 | 1 |
| Hepatobiliary | |||
| Mild hepatic | 16.6% (11.1-23.2) | 1.31 | 1 |
| Moderate hepatic | 18% (12.9-23.7) | 1.41 | 1 |
| Biochemical CoMs | |||
| Albumin levels ≥25 to <35 mmol/L | 20.7% (14.6-27.5) | 1.32 | |
| Albumin levels <25 mmol/L | 50.0% (18.4-75.3) | 4.17 | 3 |
| Other CoMs | |||
| Continuation of prednisolone therapy ≥0.3 mg/kg per day beyond D0 | 27.5% (15.3-21.1) | 1.62 | 1 |
| Prior malignancy pre-HSCT | 18.3% (2.9-44.4) | 1.82 | 2 |
| RF/comorbid condition . | 2-y TRM (95% CI) . | Multivariate analysis (HR) . | Weight . |
|---|---|---|---|
| Donor type | |||
| Mismatched donor | 24.1% (18.2- 30.5) | 2.14 | 2 |
| Conditioning regimen | |||
| TBI | 18.4% (10.9-27.5) | 1.75 | 2 |
| Infection | |||
| Presence of respiratory viral infection D-10-D0 | 31% (15-49) | 2.09 | 2 |
| Lung disease | |||
| Any respiratory structural abnormality | 23% (6-47) | 2.15 | 2 |
| CNS disease | |||
| Any CNS abnormality (CNS infection, PRES, epilepsy, and CNS structural abnormality) | 47% (29-63) | 3.68 | 3 |
| Gut disease | |||
| Active infectious diarrhea | 42% (15-67) | 1.61 | 1 |
| Hepatobiliary | |||
| Mild hepatic | 16.6% (11.1-23.2) | 1.31 | 1 |
| Moderate hepatic | 18% (12.9-23.7) | 1.41 | 1 |
| Biochemical CoMs | |||
| Albumin levels ≥25 to <35 mmol/L | 20.7% (14.6-27.5) | 1.32 | |
| Albumin levels <25 mmol/L | 50.0% (18.4-75.3) | 4.17 | 3 |
| Other CoMs | |||
| Continuation of prednisolone therapy ≥0.3 mg/kg per day beyond D0 | 27.5% (15.3-21.1) | 1.62 | 1 |
| Prior malignancy pre-HSCT | 18.3% (2.9-44.4) | 1.82 | 2 |